TY - JOUR
T1 - SPECT and PET Radiotracers in Renal Imaging
AU - Werner, Rudolf A.
AU - Pomper, Martin G.
AU - Buck, Andreas K.
AU - Rowe, Steven P.
AU - Higuchi, Takahiro
N1 - Funding Information:
Takahiro Higuchi reports financial support was provided by Japan Society for the Promotion of Science. Takahiro Higuchi reports financial support was provided by Okayama University. Steven P. Rowe reports a relationship with Progenics Pharmaceuticals Inc. that includes: consulting or advisory. Martin G. Pomper has patent with royalties paid to US patent. MGP is a co-inventor on a US patent covering 18 FDCFPyL and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. SPR is a consultant for Progenics Pharmaceuticals Inc., the licensee of 18 F-DCFPyL. TH received funding through the Okayama University “RECTOR” Program and a KAKENHI grant (21K19450) has been provided for TH from the Japan Society for the Promotion of Science. All other authors declare that there is no conflict of interest as well as consent for scientific analysis and publication.
Funding Information:
Takahiro Higuchi reports financial support was provided by Japan Society for the Promotion of Science. Takahiro Higuchi reports financial support was provided by Okayama University. Steven P. Rowe reports a relationship with Progenics Pharmaceuticals Inc. that includes: consulting or advisory. Martin G. Pomper has patent with royalties paid to US patent. MGP is a co-inventor on a US patent covering 18FDCFPyL and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. SPR is a consultant for Progenics Pharmaceuticals Inc., the licensee of 18F-DCFPyL. TH received funding through the Okayama University “RECTOR” Program and a KAKENHI grant (21K19450) has been provided for TH from the Japan Society for the Promotion of Science. All other authors declare that there is no conflict of interest as well as consent for scientific analysis and publication.
Publisher Copyright:
© 2021 The Author(s)
PY - 2022/7
Y1 - 2022/7
N2 - Diuretic scintigraphy includes single-photon emitting radiotracers for planar and single photon emission computed tomography (SPECT) imaging as well as agents for positron emission tomography (PET). These radiotracers provide split-renal functional parameters, including glomerular filtration rate, effective renal plasma flow, tubular function, and/or renal blood flow. Beyond measuring kidney function, the tracer principle also allows for the assessment of various pathophysiological processes in the renal parenchyma, for example ongoing inflammation, activation of angiotensin II type 1 receptor in patients with renovascular hypertension, deterioration of mitochondrial complex I following acute or chronic kidney injury, or characterization of indeterminate renal masses. Providing a whole-body read-out, PET also enables the assessment of kidney-organ interactions, for example cardiorenal crosstalk after primary cardiac injury. This manuscript provides an overview of established clinical applications for single-photon-emitting and PET radiotracers for renal radionuclide imaging. Future perspectives in the field will also be highlighted, such as introduction of PET-guided strategies for drug dose optimization and the recent introduction of radiotracers targeting fibroblast activation protein inhibition, which may allow differentiation between acute inflammatory vs chronic fibrosis in the kidneys.
AB - Diuretic scintigraphy includes single-photon emitting radiotracers for planar and single photon emission computed tomography (SPECT) imaging as well as agents for positron emission tomography (PET). These radiotracers provide split-renal functional parameters, including glomerular filtration rate, effective renal plasma flow, tubular function, and/or renal blood flow. Beyond measuring kidney function, the tracer principle also allows for the assessment of various pathophysiological processes in the renal parenchyma, for example ongoing inflammation, activation of angiotensin II type 1 receptor in patients with renovascular hypertension, deterioration of mitochondrial complex I following acute or chronic kidney injury, or characterization of indeterminate renal masses. Providing a whole-body read-out, PET also enables the assessment of kidney-organ interactions, for example cardiorenal crosstalk after primary cardiac injury. This manuscript provides an overview of established clinical applications for single-photon-emitting and PET radiotracers for renal radionuclide imaging. Future perspectives in the field will also be highlighted, such as introduction of PET-guided strategies for drug dose optimization and the recent introduction of radiotracers targeting fibroblast activation protein inhibition, which may allow differentiation between acute inflammatory vs chronic fibrosis in the kidneys.
UR - http://www.scopus.com/inward/record.url?scp=85122984394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122984394&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2021.12.003
DO - 10.1053/j.semnuclmed.2021.12.003
M3 - Review article
C2 - 35058040
AN - SCOPUS:85122984394
SN - 0001-2998
VL - 52
SP - 406
EP - 418
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 4
ER -